Cell surface expression of CD86 (mCD86) provides an important co-stimulatory signal which profoundly influences immune responses. In this report, we investigated the potential presence of a circulating soluble form of CD86 (sCD86) in normal individuals and patients with acute myeloid leukaemia (AML) or B cell chronic lymphocytic leukaemia (B-CLL). Circulating sCD86 was detected in the plasma of all normal individuals (1.04 ± 0.33 ng/ml, n = 51) and patients analysed. Plasma collected from AML patients in remission (n = 6) contained only low levels of sCD86 but significantly elevated levels (у2.65 ng/ml, P Ͻ 0.0001) were detected in 10/24 AML patients analysed at the time of presentation or relapse. Significantly elevated levels of sCD86 were also detected in 2/17 B-CLL patients. There was no correlation between sCD86 levels and other clinical parameters. RT-PCR analysis demonstrated that normal monocytes and dendritic cells, as well as isolated AML (n = 2) and B-CLL (n = 4) cells, expressed an alternatively spliced transcript of CD86 which encoded a soluble form absent in normal T, B and NK cells. The finding that a proportion of leukaemia patients contain elevated levels of sCD86 and that at least some leukaemic cells express sCD86 transcript suggests a potential role for sCD86 in modulating mCD86 signalling during the malignant process. Leukemia (2002) 16, 865-873.
Introduction
Optimal T cell activation requires both signalling via the Agspecific T cell receptor and a second co-stimulatory signal. 1 The most studied co-stimulatory pathway involves the interaction of two distinct B7 molecules (B7-1 (CD80) and B7-2 (CD86)) expressed on antigen-presenting cells (APC) with their T cell counter receptors CD28 and CTLA-4.
2 Both CD80 and CD86 are transmembrane glycoprotein members of the Ig superfamily [3] [4] [5] which, apart from weak CD86 expression on monocytes, are absent on normal circulating leukocytes but induced following activation on dendritic cells (DC), lymphocytes and monocytes. 2 Interaction of B7:CD28 has been shown to provide a critical second signal for T cell activation, whilst the absence of this signal results in T cell anergy. 2, 6 The role of the B7:CTLA-4 interaction is less well defined although it can in some circumstances mediate a negative regulatory signal. 7 Modulation of B7-mediated co-stimulatory signals has been shown to profoundly influence in vivo immune responses and much attention has been devoted to the manipulation of these signals for therapeutic purposes. It is clear that these signals play an important role in the development of anti-tumour responses and in a number of models the induction of increased tumour expression of B7 results in increased immunogenicity. 2 However, many other factors also influence immunogenicity and the progression of a number of haematological malignancies can occur despite constitutive expression of B7 by the malignant population. 8 Recent studies have shown that CD86 expression by malignant cells is in fact associated with a poor prognosis in both acute myeloid leukaemia (AML) and multiple myeloma (MM). 9, 10 A broad range of leukocyte cell surface antigens are released as soluble forms, many of which have agonistic, antagonistic or independent biological effects relative to their membrane bound counterparts. [11] [12] [13] Studies of in vivo soluble forms of B7 have, however, been limited. A soluble form of CD80 has been detected in human synovial fluid 14 and the presence of a soluble CD28 ligand has been described in porcine epithelial cell cultures. 15 Alternatively spliced transcripts encoding for soluble forms of porcine CD80, canine CD80 and canine CD86 have also been reported. 16, 17 Soluble forms of CD86 (sCD86), if generated in vivo, would provide a potentially powerful mechanism by which the immune system and/or malignant cells could modulate the co-stimulatory signals delivered through cell membrane CD86.
We therefore investigated the potential presence of sCD86 in vivo. Since the initiation of this study, a recent paper has reported the detection of circulating sCD86 in a small proportion of normal donors. 18 We describe the development of a higher sensitivity ELISA for the detection of sCD86 and report the presence of sCD86 in all normal human plasma tested. We also demonstrate elevated sCD86 levels in a number of patients with AML and chronic lymphocytic leukaemia (CLL).
Materials and methods

Reagents
The monoclonal antibody (mAb) MAB141 (CD86, IgG 1 ) and polyclonal goat anti-CD86 (GA86) were obtained from R&D Systems (Minneapolis, MN, USA). The mAb HA5.2B7 (CD86, IgG 2b ), HB15a (CD83, IgG 2b ) and B9.11 (CD8, IgG 1 ) were obtained from Beckman Coulter (Fullerton, CA, USA). The antibody MOPC21 (mouse IgG 1 ) and purified goat Ig were obtained from Sigma (St Louis, MO, USA). Biotinylated rabbit anti-goat Ig (bio-RAG) was obtained from Dako (Glostrup, Denmark) and cross-reactivity with mouse Ig removed by passage over mouse IgG agarose (Sigma). Streptavidin-HRP and DAKO TMB one-step substrate system was obtained from Dako. CD86-Ig was a kind gift from Dr Robert Peach (Bristol Myers Squibb, Princeton, NJ, USA). Unconjugated and PEconjugated CD3, CD14, CD19, CD56, CD33, CD11b and HLA-DR mAb were obtained from Becton Dickinson (San Jose, CA, USA).
Leukemia
Patient and control samples
Blood was obtained from normal donors and leukaemia patients with appropriate informed consent according to ethical committee guidelines and collected into EDTA. Samples were then centrifuged at low speed (300 g, 5 min) and the plasma fraction recovered. The plasma was then further centrifuged (10 000 g, 30 min) and the non-sedimented material stored frozen prior to analysis. Fifty-one normal individuals were investigated. Plasma samples from 30 individual AML patients were analysed. Of these patients, 24 had active disease (ie were at presentation (n = 22) or relapse (n = 2)), whilst six were in chemotherapy-induced remission (n = 6) at the time of initial sample collection. The clinical details of those patients with active disease (n = 24) is shown in Table 1 . Three of the newly presented and one of the relapsed AML patients were analysed over the course of their treatment. Seventeen B-CLL patients were analysed, all of whom had elevated white blood cell (WBC) counts at the time of analysis. The diagnosis of CLL or AML and their subtypes was based on clinical findings and established morphological, cytochemical and cytofluorimetric features of the peripheral blood and/or bone marrow cells. AML patients were treated either with standard combination intensive remission induction regimens or oral palliative agents according to patient/physician preference. Remission was defined as the presence of less than 5% blasts cells in the bone marrow based on morphology.
Cells and cell lines
Human peripheral blood mononuclear cells (PBMC) were isolated by centrifugation over Ficoll/Paque (Amersham Pharma- 
sCD86 ELISA
Ninety-six-well microtitre plates (Costar, Corning, NY, USA) were pre-coated (2 h, 37°C) with CD86 mAb (37301.111) or isotype control antibody (MOPC21) at 2.5 g/ml in a solution (12.5 g/ml) of bovine serum albumin (Gibco) in PBS (BSA/PBS). Non-specific binding was then blocked by incubation with 2% BSA/PBS prior to application of samples (150 l). Following incubation (16 h, 4°C), wells were incubated (1 h, 37°C) with GA86 at 1 g/ml in diluent (0.4% BSA/PBS) prior to incubation (1 h, 37°C) with bio-RAG (1:5000 in diluent). Streptavidin HRP (Dako) was then added in a 1 in 10 000 dilution (in 1% BSA/PBS) and incubated for 1 h at 37°C. Between each step plates were thoroughly washed with 0.1% Tween 20/PBS. Plates were developed using TMB substrate, the reaction stopped by acidification (3 M H 2 SO 4 , 1 M HCl) and OD read at 450 nm.
Standard curves for the estimation of sCD86 concentration were generated using serial dilutions of CD86-Ig prepared in media (10% FCS/RPMI 1640) supplemented with Hepes (40 mM, pH 7.4) and diluted 2:1 (v/v) with sample diluent (2% Casein, 0.2% Tween 20). The interassay (n = 12) coefficient of variation (CV) was 13% and intra-assay CV was 3.9%.
Separated serum and plasma samples were centrifuged (10 000 g/30 min) prior to analysis or storage (−20°C). In a number of experiments an additional centrifugation step (100 000 g, 1 h) was also carried out. Samples were diluted 2:1 (v/v) with sample diluent prior to ELISA analysis. Each sample was measured in duplicate and wells coated with the isotype control antibody MOPC21 were used as a measure of the non-specific background for each individual sample. In a number of experiments (n = 8) samples were immunodepleted prior to analysis. Briefly, immunomagnetic beads (BioMag magnetic microspheres, PerSeptive Biosystems, Framingham, MA, USA) were pre-incubated with CD86 (HA5.2B7) or control (HB15a) mAb then, following washing, incubated (o/n, 4°C) with plasma samples.
Statistics
The Tukey-Kramer procedure was used to determine the significance of difference between groups. Survival was calculated according to Kaplan and Meier. A P value of less than 0.05 was considered to indicate significance.
Immunoabsorption and Western blotting
Cell lysates were prepared from the B cell line Raji and IFN␥ activated non-T cells (ER − PBMC) by solubilisation in lysis buffer (0.5% TritonX-100, 0.25% CHAPS) as previously described. 19 Cell lysates and plasma were analysed by immunoabsorption in combination with Western blotting using a modification of a previously described method. 20 Briefly, MaxiSorp microtiter plates (Nunc, Roskilde, Denmark) were coated with either CD86 or isotype control mAb (2.5 g/ml in 12.5 g/ml BSA/PBS) then blocked with 2% BSA/PBS. Plates were then incubated (o/n, 4°C) with either cell lysate (diluted 1:1 with 2% CsT) or plasma (diluted 5:1 with 2% CsT). Following washing and serial elution of wells, bound antigen was separated on a 10% sodium dodecyl-sulphate (SDS) polyacrylamide gel under reducing conditions and blotted on to nitrocellulose (Hybond-C extra; Amersham). Blots were blocked with 2% BSA/PBS then serially incubated (1 h, Leukemia 37°C) with GA86 (0.2 g/ml), RAG-bio (1 in 2000) and AV-HRP (1 in 10 000). Blots were washed in 0.1% Tween between each step and signals visualised by chemiluminescence using Super Signal (Pierce, Rockford, IL, USA).
Detection and sequencing of CD86 mRNA variants
Total RNA was extracted from human cell lines using Trizol reagent (Life Technologies, Auckland, NZ) and from purified leukocyte populations using the RNAeasy Kit (Qiagen, Hilden, Germany) as per the manufacturers' instructions. Single-strand cDNA was synthesised in a final volume of 40 l containing 2.5 M oligonucleotide-d(T) 18 primer, 100 U SuperScript II reverse transcriptase (Life Technologies) and 20 l RNA. Samples were incubated at 42°C for 1 h and stored at −20°C until use. A RT-PCR (RT-PCR TM ) was performed using primers CD86 U4 (5Ј-TGCTCATCTATACACGGTTAC-3Ј) and CD86 D3 (5Ј-TTTCTTGGTCTGTTCACTCTC-3Ј) which amplified the region spanning exon 6. A second RT-PCR (RT-PCR SOL ) was performed using primers U4 and D5 (5Ј GTGTTGGTTCCTAT-AGAGAA-3Ј) to specifically amplify transcripts lacking exon 6. RT-PCR was performed as follows: 94°C for 2 min, then 35 cycles at 94°C for 30 s, 59°C for 30 s and 72°C for 1 min, followed by a final extension step at 72°C for 5 min. PCR products were separated on 2% agarose gels and visualised by SYBR gold staining (Life Technologies). RNA integrity and cDNA synthesis was verified by amplifying ␤ 2 -microglobulin (␤ 2 m) using primers ␤ 2 m U1 (5Ј-TTAGCTGTGCTCGCGCTAC TCT-3Ј) and ␤ 2 m D1 (5Ј-TCGGATTGATGAAACCCAGACA-3Ј) using the above protocol.
In order to sequence both the full-length and soluble forms of CD86, RT-PCR was performed using CD86 T3-U4 (5Ј-AATT AACCCTCACTAAAGCTTGCTCATCTA-3Ј) and CD86 T3-D4 (5Ј-AATTAACCCTCACTAAAGGATCCTTATTACTCATGGT AATGTC-3Ј). Two transcripts were amplified and these were excised from the gel and purified using the Concert gel purification kit (Life Technologies). The PCR product was then directly sequenced by the dideoxy chain termination method using the Thermo Sequenase Primer Cycle Sequencing kit (Amersham Pharmacia Biotech, Auckland, New Zealand) and IRD 40 -labelled primers (MWG-Biotech, Ebersberg, Germany) and the reactions separated on a Li-Cor automated sequencer (Lincoln, NE, USA).
Results
Establishment of a sCD86 ELISA
A sandwich ELISA for the detection of sCD86 was developed using a CD86 mAb as the capture reagent and polyclonal anti-CD86 for detection. A CD86-Ig fusion protein was used as the standard and as shown in Figure 1a the lower detection limit of the ELISA was 0.3 ng/ml. The specificity of the ELISA was confirmed using control capture ( Figure 1a ) and detection reagents (data not shown) and the assay showed no crossreactivity with either CD80-Ig or hIg (Figure 1b) .
Levels of sCD86 in normal and patient plasma
Plasma was collected from both normal donors and patients with either AML or B-CLL. The levels of sCD86 present were then determined by ELISA. All normal and patient plasma ana- lysed contained detectable levels of sCD86 (Figure 2 ). Normal plasma (n = 51) had a mean sCD86 concentration (± s.d.) of 1.04 ± 0.33 ng/ml (range 0.44 to 1.67 ng/ml). Similar levels were observed in the majority of patient samples but a number (12/47) had significantly elevated (у2.65 ng/ml) sCD86 levels (P Ͻ 0.0001).
The sCD86 levels in the majority of B-CLL patients analysed (15/17) was not significantly different from that of normals, however, significantly elevated levels were observed in two of these patients (5.04 and 5.8 ng/ml, Figure 2) . Plasma samples from individual AML patients (n = 30) were divided into two groups -those from patients with active disease (ie at presentation or relapse, n = 24) and those from patients in chemotherapy-induced remission (n = 6) at the time of initial sample collection. Analysis of plasma collected from AML patients with active disease demonstrated that a number (10/24) had significantly elevated (у2.65 ng/ml) levels of plasma sCD86 (Figure 2 , Table 1 ). In contrast the plasma collected from 14 of the 24 AML patients with active disease and from all the AML patients in chemotherapy-induced remission (n = 6) contained only low or normal levels of sCD86. Although patient numbers were small, when patient characteristics such as age, sex, WBC count, FAB subtype, CRP levels and % circulating blasts were compared there was no obvious correlation between any of these characteristics ELISA analysis of sCD86 levels in plasma. Scattergram of sCD86 levels in plasma obtained from normal donors, B-CLL patients, AML patients with active disease and AML patients in remission. Individual AML patients are represented by a single data point.
and the level of sCD86 detected in patients with active disease (Table 1 ). The expression of mCD86 by the circulating AML blasts was analysed in 12 of the 24 AML patients with active disease (Table 1) . Although blast expression of mCD86 was observed in those patients with the highest levels of sCD86 there was, overall, no correlation between the level of blast mCD86 expression and plasma sCD86 levels in AML patients.
Both cytogenetic characteristics and blast expression of CD56 have prognostic significance in AML. In this study cytogenetic analysis was performed on 16 of the 24 AML patients with active disease (Table 1 ) and blast expression of CD56 was analysed in all 24 patients (data not shown). Of the six patients who had poor prognosis based on their cytogenetic characteristics (AML No. 3, 10) or expression of CD56 (AML Nos 4, 6, 9, 23), five had elevated plasma sCD86 levels whilst only one (AML No 23) had low/normal levels.
Nine of the AML patients analysed in this study had been both intensively treated and had their subsequent clinical outcomes monitored for at least 6 months. Within this group four patients (AML Nos 13, 19, 20, 22) had normal sCD86 levels at presentation and of these, three survived Ͼ12 months. In contrast, of the five patients in this group who had high sCD86 levels at presentation (AML Nos 1-3, 6, 8), only one survived Ͼ7 months. However, survival analysis of this patient group demonstrated no significant difference between those patients presenting with high or normal sCD86 levels. This may reflect the low number (n = 9) of patients able to be analysed.
Changes in sCD86 during treatment of AML
The observation that only AML patients with active disease contained elevated plasma levels of sCD86 suggested that, in at least some AML patients, sCD86 levels may reflect disease status. The changes in sCD86 levels during treatment were therefore analysed in four AML patients for whom plasma samples, collected at different time points during treatment, were available (Figure 3) . Three of the analysed AML patients (AML Nos 1-3) had elevated sCD86 levels at presentation and these levels then steadily declined following the commencement of chemotherapy, becoming normal by the time of first remission. Both patient AML No. 1, who had a WBC count within the normal range at presentation, and patient AML No. 2, who had an elevated WBC count at presentation, showed a parallel decline in both WBC count and sCD86 levels following commencement of chemotherapy. Patient AML No. 3 had a low WBC count and high sCD86 levels at presentation and showed a similar decline in sCD86 levels following treatment. Patient AML No. 4 was in remission at the time the first sample was collected and had both a low WBC count and low sCD86 levels prior to relapse, when both the WBC count and plasma sCD86 levels rapidly increased. Following palliative treatment both sCD86 levels and the WBC count were reduced.
The observation that two of these patients had only low or normal WBC counts at the time at which their sCD86 levels were elevated suggests that these two parameters are not directly associated in AML. There was no correlation between sCD86 and CRP levels in AML patients at presentation (Table  1) and although CRP values increased significantly in patients AML Nos 1-3 at times during their treatment (data not shown), there was a lack of correlation between sCD86 and CRP levels in these patients throughout the monitored time periods. This, together with the observation that AML patients in remission at the time of initial analysis had both normal sCD86 levels ( Figure 1 ) and elevated CRP levels (16-83 mg/l, data not shown), suggests increased sCD86 levels are not solely the result of the types of inflammatory events which give rise to increased CRP levels.
Leukemia
In a number of experiments CD86-Ig was added to the plasma samples with reduced sCD86 levels. The addition of CD86-Ig resulted in the expected increase in ELISA signal detected demonstrating that the decline in plasma sCD86 levels observed following chemotherapy treatment was not due to a treatment-associated inhibition of sCD86 detection (data not shown).
Specificity of sCD86 detection
In order to confirm the specificity of the sCD86 signal detected in plasma, a number of samples were immunodepleted with a third-party CD86 antibody prior to analysis by ELISA. As shown in Figure 4a , a single round of immunodepletion specifically reduced the sCD86 ELISA signal observed in both normal and AML plasma by greater than 80%. Ultracentrifugation (100 000 g, 1 h) of plasma prior to ELISA analysis did not significantly reduce the observed levels of sCD86, confirming the soluble nature of the detected material (n = 8, data not shown). The addition of small amounts of CD86-Ig (1-2 ng/ml) to the plasma of normal donors (n = 8, data not shown) increased the levels of sCD86 detected in these samples by the expected amount. These results demonstrate that the difference in sCD86 levels detected in the plasma of normal donors and some leukemia patients is not due to the presence, in normal plasma, of a factor that inhibits the detection of sCD86. Western blotting analysis was performed in order to further confirm the specificity of the sCD86 ELISA and to determine the relative m.w. of the sCD86 detected. This analysis was carried out on the material eluted from the wells of an ELISA plate which had been coated with capture mAb and incubated with either whole cell lysates or plasma from AML patients with elevated sCD86 levels. A single band was specifically detected in whole cell lysates whose m.w. corresponded to that previously reported for membrane CD86 (Figure 4b) . A single band of slightly smaller m.w. (ෂ70 kDa) was specifically detected in all four AML patient plasma samples analysed.
Detection of an alternate CD86 transcript
The presence of an alternatively spliced form of CD86 mRNA which lacks the exon encoding the transmembrane (TM) region has been previously described in a study of canine CD86 mRNA. RT-PCR analysis was undertaken to detect the presence of a similar alternate CD86 transcript in human cells. The RT-PCR TM utilised primers spanning the exon encoding the Tm region (exon 6, Figure 5a) . Electrophoresis of the PCR products on an agarose gel identified the presence of two transcripts (Figure 5b ). Direct sequencing of PCR products confirmed the larger band corresponded to the published CD86 (1) PBMCs prepared from normals and AML patients, (2) purified AML blasts, and (3) purified CD19
+ cells from normals and three representative CLL patients. A ␤ 2 microglobulin RT-PCR was performed to establish the integrity of the cDNA. PCR products were visualised by SBYR Gold staining.
sequence (mCD86) whilst the smaller band (sCD86) had a deletion from nucleotides 832-977 (data not shown). Based on the genomic structure of the human CD86 gene this cDNA is generated by the deletion, through alternate splicing of exon 6 which encodes the TM region.
A second RT-PCR (RT-PCR SOL ) was established to specifically amplify the sCD86 transcript alone. This PCR utilised the same upstream primer but in combination with a primer specific for the sequence, at the junction of exon 5 and exon 7, which is generated following deletion of exon 6 (Figure 5a ). Both PCR analysis gave the same qualitative results with respect to sCD86 mRNA detection although RT-PCR SOL was clearly more sensitive (Figure 5b, c) .
871
RT-PCR analysis of purified normal PBMC populations demonstrated that mCD86 mRNA was constitutively expressed by monocytes, peripheral blood DC (PBDC) and B cells whilst sCD86 mRNA expression was restricted to monocytes and PBDC. T cells and NK cells lacked expression of both transcripts (Figure 5b) . Analysis of DC generated by the in vitro culture of monocytes in the presence of IL-4, GMCSF and LPS demonstrated that these cells, unlike circulating DC, express only mCD86 transcript (data not shown).
CD86 transcripts in leukaemic cells
RT-PCR analysis of PBMC prepared from two AML patients (AML Nos 4, 5) with elevated WBC counts (Ͼ94% blasts) and elevated plasma levels of sCD86 revealed the presence of both mCD86 and sCD86 transcripts (Figure 5c ). The phenotype of the blast populations of two additional AML patients (AML Nos 6, 14) enabled those blasts to be separated, by sorting, from any residual normal monocytes present. Although patient AML No. 14 had only low levels of plasma sCD86, the purified blasts (Ͼ98% purity) from both patients expressed both mCD86 and sCD86 transcripts.
The expression of mCD86 and sCD86 transcripts was also detected in PBMC prepared from CLL patients, all of whom had elevated WBC counts (n = 9, data not shown). The CD19 + CLL cells were purified (Ͼ98%), by sorting, from four patients with normal plasma levels of sCD86. RT-PCR confirmed that these purified cells expressed both mCD86 and sCD86 transcripts despite the absence of sCD86 transcripts in preparations of normal B cells (Figure 5c and data not shown).
The expression of sCD86 and mCD86 transcripts by human cell lines was also analysed by RT-PCR. All B cell and HDderived cell lines analysed expressed transcripts for both sCD86 and mCD86 whilst the T cell lines lacked these transcripts (Table 2) . With the exception of K562, all myeloid, acute promyelocytic and monocytic cell lines tested express mCD86 transcript. Expression of sCD86 transcript by these cell lines is, however, more restricted, being strongly Table 2 Cell line expression of sCD86 and mCD86 mRNA
Cell line RT-PCR mCD86 sCD86
PCR product as visualised on agarose gel; (−) negative; (+/−) weakly positive; (+) strongly positive.
Leukemia expressed only in the monocytic cell line THP-1 and weakly in the promyelocytic cell lines HL60 and KG-1.
Discussion
In the present study we demonstrate the presence, in all individuals analysed, of a circulating soluble form of CD86 which was present at significantly elevated levels in 12% of B-CLL patients and 40% of AML patients with active disease. Membrane CD86 (mCD86) provides a co-stimulatory signal critical for the regulation of T cell responses. 7 However studies on the potential release and significance of in vivo generated sCD86 as a modulator of mCD86-mediated signals have been limited. A recent study 18 reported the detection of sCD86 at relatively high levels in 16% of normal donors, whilst the majority of samples contained no detectable sCD86. Although 40 cancer patients (of unspecified diagnosis) were also analysed, sCD86 was detected in only 15% and those levels were within the normal range. The sensitivity of the ELISA used in that study was approximately 10-fold lower than that used in our study and it is unclear whether the higher values detected in some donors was due to differences in the ethnic background and/or immune status of the study group or resulted from the presence of insoluble, possibly membrane-associated CD86. All samples utilised in this study were centrifuged to remove membrane fragments prior to analysis and ultracentrifugation confirmed the soluble nature of the detected material. The specificity of the ELISA used in this report was, in addition, confirmed by both immunodepletion and Western blotting.
Soluble forms of membrane molecules are typically released as either the product of differential splicing of mRNA or enzymatic cleavage of the cognate membrane form. 11 The expression of a variant of CD86 mRNA in which the exon encoding the Tm region was deleted has been described in both canine PBMC 16 and circulating human monocytes. 18 In this report we demonstrate that within normal PBMC populations both circulating DC and monocytes express the sCD86 transcript which is also expressed by both AML and CLL cells, in at least some patients. However, because this study analysed sCD86 transcript expression in only a small group of patients further analysis is required to determine the true proportion of AML and CLL patients that have malignant populations expressing this transcript. Expression of sCD86 transcript appears broader in malignant than normal populations as although absent in normal B cells it is expressed by B cell lines, isolated CLL blasts and HD-derived cell lines, which are also thought to have a B cell derivation. 21 The observation that B cells and in vitro-generated DC express only mCD86 mRNA provides strong evidence that the expression of sCD86 and mCD86 mRNA is regulated independently. Although these data suggest sCD86 is generated primarily by alternate splicing the possibility that sCD86 can also be generated by proteolytic cleavage of mCD86 cannot be excluded.
The observation that only low sCD86 levels are observed in normal plasma, together with the fact that elevated sCD86 levels in AML patients are reduced following chemotherapyinduced remission, suggests that the high sCD86 levels observed in some leukaemia patients are the result of sCD86 release either directly from, or as a response by other cells to, the malignant population. The possibility that increases in sCD86 levels are the result of other immunological events cannot be totally excluded. However, the observation in this study, that sCD86 levels are not directly related to CRP levels does suggest that increases in sCD86 are not solely part of a broad inflammatory response. Interestingly, leukaemic blasts purified from both AML and CLL patients with low plasma levels of sCD86 were found to express both mCD86 and sCD86 transcripts. A number of cell types which constitutively express mCD86 mRNA only express the mCD86 protein following activation. 4, 22 The release of sCD86 by malignant and normal cells expressing sCD86 mRNA may also occur only in response to particular stimuli. The detection of only normal sCD86 levels in the majority of patients may therefore reflect a more localised release or the absence of appropriate stimuli at the time of analysis.
The biological effects of in vivo-generated sCD86 and the functional significance of elevated levels of sCD86 in leukaemia patients are at present unknown. A number of studies have demonstrated that recombinant, soluble forms of CD86 can, depending on the experimental sytem utilised, either inhibit or enhance immune responses. 18, [23] [24] [25] [26] [27] It is known that many tumour cells including CLL and AML blasts release soluble molecules which can inhibit anti-tumour responses 11, 13, [28] [29] [30] [31] [32] and it is possible that sCD86 release also represents a mechanism by which tumour cells escape immune responses. The functional activity of in vivo-generated sCD86 will, however, be dependent on a number of factors including its glycosylation state, its level of oligomerisation and the kinetics of its release relative to mCD86 expression. 33 It is clear from both in vivo and in vitro studies that mB7 co-stimulation plays an important role in the generation of anti-tumour responses. However, many factors influence tumour immunogenicity and tumour cell expression of B7 does not in itself confer immunogenicity. Many haematological malignancies express B7 constitutively 8 and in both AML and multiple myeloma (MM) patients membrane expression of CD86 is in fact associated with a considerably poorer prognosis. 9, 10 The levels of mCD86 in AML and MM were in common with sCD86 levels in AML patients, not obviously correlated to other clinical and prognostic parameters. It is presently unknown whether mCD86 expression by these malignant cells plays a direct role in tumour progression or is solely a marker of inherently more aggressive or treatmentresistant tumours. The results of this study demonstrate that although blast expression of mCD86 was observed in a number of the patients with the highest levels of sCD86 there was not, overall, a strict correlation between blast expression of mCD86 and sCD86 levels in AML patients. Interestingly, high sCD86 levels were observed in five of the six patients who had a poor prognosis based on their expression of CD56 or cytogenetic characteristics. Comparison of the survival times of AML patients who received intensive chemotherapy also suggested that those patients with elevated sCD86 levels had shorter survival times than those patients with low or normal levels. However, further studies on a larger group of patients will be required to determine if these observations are in fact statistically significant and to determine what level of correlation there is between sCD86 levels and other defined prognostic markers.
The absence or low level expression of mB7 by malignant cells is thought to represent one mechanism by which they escape immunosurveillance. The provision of increased mB7 expression at the time of tumour challenge is now a central theme of many cancer immunotherapy protocols 34 and the administration of soluble recombinant B7-Ig has also been proposed as a means of inducing tumour immunity. 25 The demonstration in this study that a circulating soluble form of CD86 is detectable in all normal individuals, that a proportion of leukaemia patients have elevated sCD86 levels and that DC, monocytes and at least some leukaemic cells express sCD86 transcript suggests that sCD86 may have a role in modulating the co-stimulatory signals delivered via mCD86. The question of whether sCD86 represents a means of enhancing or inhibiting co-stimulatory signals has important implications with regard to cancer immunotherapy protocols. We are therefore currently undertaking further studies to determine the prognostic and functional significance of sCD86 in AML and other malignancies.
